- Home
- TGTX vs VSAT Comparison
TGTX vs VSAT Comparison
Compare TGTX & VSAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TGTX
- VSAT
- Stock Information
- Founded
- TGTX 1993
- VSAT 1986
- Country
- TGTX United States
- VSAT United States
- Employees
- TGTX N/A
- VSAT N/A
- Industry
- TGTX Biotechnology: Pharmaceutical Preparations
- VSAT Radio And Television Broadcasting And Communications Equipment
- Sector
- TGTX Health Care
- VSAT Technology
- Exchange
- TGTX Nasdaq
- VSAT Nasdaq
- Market Cap
- TGTX 4.2B
- VSAT 4.3B
- IPO Year
- TGTX 1995
- VSAT 1996
- Fundamental
- Price
- TGTX $33.09
- VSAT $31.21
- Analyst Decision
- TGTX Strong Buy
- VSAT Buy
- Analyst Count
- TGTX 4
- VSAT 8
- Target Price
- TGTX $42.50
- VSAT $22.43
- AVG Volume (30 Days)
- TGTX 2.0M
- VSAT 4.2M
- Earning Date
- TGTX 11-03-2025
- VSAT 11-05-2025
- Dividend Yield
- TGTX N/A
- VSAT N/A
- EPS Growth
- TGTX N/A
- VSAT N/A
- EPS
- TGTX 0.36
- VSAT N/A
- Revenue
- TGTX $454,069,000.00
- VSAT $4,564,165,000.00
- Revenue This Year
- TGTX $82.58
- VSAT $5.21
- Revenue Next Year
- TGTX $44.99
- VSAT $3.09
- P/E Ratio
- TGTX $88.20
- VSAT N/A
- Revenue Growth
- TGTX 30.96
- VSAT N/A
- 52 Week Low
- TGTX $21.16
- VSAT $6.69
- 52 Week High
- TGTX $46.48
- VSAT $33.85
- Technical
- Relative Strength Index (RSI)
- TGTX 54.72
- VSAT 59.07
- Support Level
- TGTX $31.34
- VSAT $28.92
- Resistance Level
- TGTX $32.56
- VSAT $33.40
- Average True Range (ATR)
- TGTX 1.03
- VSAT 1.94
- MACD
- TGTX -1.33
- VSAT -0.33
- Stochastic Oscillator
- TGTX 99.06
- VSAT 56.99
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.
About VSAT ViaSat Inc.
Viasat Inc provides bandwidth technologies and services in three segments: communication services and defense and advanced technologies. The communication services segment provides a wide range of broadband and narrowband communications solutions across government and commercial mobility markets, as well as for residential and enterprise fixed broadband customers: and the defense and advanced technologies segment develops and offers a diverse array of resilient, vertically integrated solutions to government and commercial customers, leveraging core technical competencies in encryption, cyber security, tactical gateways, modems and waveforms. A large majority of the firm's revenue is generated from communication services segment.